# An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Study · id `cardio:ct-nct07517263` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07517263](<https://clinicaltrials.gov/study/NCT07517263>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07517263

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 5700 participants.

## Technical summary

Registry record NCT07517263. Allocation not applicable; no masking; primary purpose treatment. Start 2026-05-11 (actual); primary completion 2030-01-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 5700 participants (planned count; ClinicalTrials.gov record NCT07517263, source copy `cardio:ctgov-nct07517263-2026-10-14`, retrieved 2026-10-26)
- Started: 2026-05-11 (actual) (ClinicalTrials.gov record NCT07517263, source copy `cardio:ctgov-nct07517263-2026-10-14`, retrieved 2026-10-26)
- Primary completion: 2030-01-09 (anticipated) (ClinicalTrials.gov record NCT07517263, source copy `cardio:ctgov-nct07517263-2026-10-14`, retrieved 2026-10-26)
- Completion: 2030-01-09 (anticipated) (ClinicalTrials.gov record NCT07517263, source copy `cardio:ctgov-nct07517263-2026-10-14`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Czechia; Denmark; France; Germany; Greece; Hong Kong SAR China; Hungary; Iceland; India; Israel; Italy; Japan; Mexico; Netherlands; Norway; Poland; Portugal; Puerto Rico; Romania; Russia; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT07517263, source copy `cardio:ctgov-nct07517263-2026-10-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07517263-2026-10-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- Condition: Cardiovascular Disease and Lipoprotein(a)
- Intervention (Drug): Pelacarsen (TQJ230)
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: eb2bc18dcc794e68100dcba772b8b2cde75faf39e62cf993b25ed693dac87915
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
